- Merck's (MRK) plan to sell its portfolio of popular consumer brands including Coppertone sun screen and Claritin allergy pills is kicking into high gear, with consumer and healthcare companies expected to put in bids that could top $10B, WSJ reports.
- MRK is said to have already received preliminary offers for the business, and final bids likely will be due late next month.
- After recent talks for a swap of the business for Novartis' vaccine and animal health units fizzled, MRK has turned its attention toward an outright sale; CEO Ken Frazier has said the consumer business is heavily concentrated in North America and lacks sufficient global scale.
From other sites
at Nasdaq.com (Mon, 12:16PM)
at Investopedia (Apr 10, 2015)
at Zacks.com (Apr 9, 2015)
at Zacks.com (Mar 26, 2015)
at 4-traders.com (Mar 24, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs